Pfizer no longer going to conduct interim analysis for Duchenne gene therapy study by end of year

Pfiz­er no longer plans to read out an in­ter­im analy­sis on its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py pro­gram by the end of the year, it dis­closed at an in­vestor event last week. In­stead, the phar­ma com­pa­ny plans to wait for the fi­nal analy­sis.

The Phase III study for for­dadis­tro­gene mova­parvovec is ex­pect­ed to be com­plet­ed in April, ac­cord­ing to the fed­er­al clin­i­cal tri­als data­base. In Oc­to­ber, Pfiz­er had guid­ed that there could be an in­ter­im analy­sis at year-end and a fi­nal analy­sis in the sec­ond half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.